News | March 21, 2026
Pfizer warns shareholders against Tutanota’s mini-tender offer
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Subscribe To Our Newsletter & Stay Updated
